TERT promoter mutations alone were significantly associated with age ≥ 55 years (p = 0.001), tumor size > 1 cm (p < 0.001), multifocal PTCs (p < 0.001), extrathyroidal extension (p < 0.001), PTC variants (p = 0.001), T3–4 (p < 0.001)/M1 stages (p < 0.001), stage III/IV (p < 0.001), and more adjuvant RAI therapy (p < 0.001). This evidence concerns the gene TERT and neoplasm.